Miraculins and the Fox Chase Cancer Center in Philadelphia plan to validate colorectal cancer biomarkers that Miraculins acquired last year from Europroteome, the companies said this week.
Miraculins and the Fox Chase Cancer Center in Philadelphia plan to validate colorectal cancer biomarkers that Miraculins acquired last year from Europroteome, the companies said this week.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.